^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

GBM6-AD

i
Other names: GBM6-AD, GBM6-AD lysate protein vaccine
Associations
Company:
University of Minnesota
Drug class:
Immunostimulant
Related drugs:
Associations
1m
Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma (clinicaltrials.gov)
P1, N=28, Completed, Jennie Taylor | Active, not recruiting --> Completed
Trial completion
|
CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10)
|
CXCL10 expression
|
GBM6-AD • Hiltonol (poly-ICLC)
9ms
New P1 trial
|
Zyclara (imiquimod) • CD200AR-L • GBM6-AD
1year
Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma (clinicaltrials.gov)
P1, N=28, Active, not recruiting, Jennie Taylor | Trial completion date: Aug 2023 --> Aug 2024
Trial completion date
|
CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CD4 (CD4 Molecule)
|
CXCL10 expression
|
GBM6-AD • Hiltonol (poly-ICLC)
2years
Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma (clinicaltrials.gov)
P1, N=28, Active, not recruiting, Jennie Taylor | Trial primary completion date: Feb 2023 --> Aug 2022
Trial primary completion date
|
CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CD4 (CD4 Molecule)
|
GBM6-AD • Hiltonol (poly-ICLC)